Merck said on Tuesday a study showed its injectable version of cancer drug Keytruda was not inferior to the currently ...
Merck (NYSE:MRK) marked a major milestone in its bid to introduce a new formulation for its famous cancer therapy ...
On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...
In addition to the Phase 3 MK-3475A-D77 trial, Merck’s subcutaneous pembrolizumab clinical development program includes the ...
US pharma giant Merck & Co (NYSE: MRK) today announced positive top-line results from the pivotal Phase III MK-3475A-D77 ...
Analysts are split on whether the positive trial results will help Merck stem future Keytruda losses as the mega-blockbuster ...
Merck plans to discuss the data with regulators as it lags rivals Roche and Bristol Myers in bringing forward a subcutaneous ...
Tuesday said its Phase 3 study evaluating subcutaneous Keytruda with Alteogen Inc.'s berahyaluronidase alfa in ...
Merck's Keytruda sales rose 17.2% YoY to $7.43 billion. Find out why MRK stock's strong fundamentals and high dividend yield ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback